Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Infectious Disease

The Three-Phase Treatment Strategy

At a Glance

Talaromycosis treatment usually has three stages: 14 days of intravenous liposomal Amphotericin B, about 10 weeks of oral itraconazole, and longer-term maintenance to prevent relapse. People with HIV also need coordinated HIV treatment and monitoring for IRIS.

Treating talaromycosis is an intensive process that requires a carefully timed, three-phase strategy. Because this fungus can hide deep within your immune cells, treatment usually spans several months to ensure the infection is completely cleared and does not return [1][2]. Please note this outline reflects standard guidelines for adults with HIV-associated disease; your infectious disease specialist will individualize this if you do not have HIV, are pregnant, or have central nervous system involvement.

Phase 1: Induction (The First 2 Weeks)

The goal of the induction phase is to rapidly clear the fungus from your bloodstream [1].

  • The Preferred Medication: Modern guidelines commonly recommend intravenous (IV) Amphotericin B (specifically Liposomal Amphotericin B, which is less toxic to the kidneys than the deoxycholate formulation) for the first 14 days [1][3].
  • Why IV Amphotericin? A major clinical trial in advanced-HIV patients found that those given Amphotericin B induction had an 88.7% 24-week survival rate, compared to 79% for those who started with oral Itraconazole [1]. Amphotericin B clears the fungus from the blood much faster [1][4].
  • The Trade-off (Side Effects): Amphotericin B is powerful but causes:
    • Infusion Reactions: Fever, chills, or shaking during the IV drip [1].
    • Kidney Stress: It can affect kidney function (renal toxicity) [1][5].
    • Electrolyte Loss: It causes the body to lose potassium and magnesium [1].
    • Anemia: It can lower your red blood cell count, making you feel very tired [6].

Phase 2: Consolidation (The Next 10 Weeks)

Once the initial 14-day IV treatment is done, you will transition to the consolidation phase. This typically involves taking Itraconazole (usually 200mg twice daily) for about 10 weeks [2][3].

This phase is critical because stopping early increases the risk of a relapse [1]. How you take Itraconazole depends entirely on the specific formulation your pharmacy provides, as they are not interchangeable: capsules must be taken with a full meal and require stomach acid, while the oral solution is generally taken on an empty stomach [7][8]. Do not alter your use of antacids or proton-pump inhibitors without consulting your doctor or pharmacist.

Phase 3: Maintenance (Long-term Prevention)

The final phase is maintenance therapy (secondary prophylaxis). This involves a lower daily dose of Itraconazole [2].

  • For patients with HIV, this phase usually continues until you have completed a minimum treatment period (often 12 months) and your CD4 count stays above 100 cells/µL for at least 6 months with effective viral suppression [3].
  • Non-HIV patients must not stop maintenance without specialist advice.

For Patients with HIV: Timing and IRIS

If you have HIV, the timing of your Antiretroviral Therapy (ART) is vital.

  • Early Start: Research suggests coordinating with your care team to start ART within about 1 to 2 weeks of beginning antifungal treatment to improve overall survival [9][3].
  • Understanding IRIS: As your immune system wakes up, it may trigger an inflammatory response called Immune Reconstitution Inflammatory Syndrome (IRIS) [10].
  • What to Look For: IRIS can cause fevers or worse coughing, usually within the first two weeks of starting ART [10][11]. However, worsening symptoms could also mean drug resistance, failure to absorb the medication, or a new infection, so you must seek prompt clinical assessment for any new symptoms [10].
Phase Duration Primary Medication Purpose
Induction 14 Days Amphotericin B (IV) Rapidly clear fungus from blood [1]
Consolidation 10 Weeks Itraconazole (Oral) Eradicate lingering fungal cells [2]
Maintenance Long-term Itraconazole (Oral) Prevent the infection from returning [3]

Common questions in this guide

What are the three stages of treatment for talaromycosis?
Treatment usually starts with about 14 days of intravenous liposomal Amphotericin B for induction. It is followed by about 10 weeks of oral itraconazole for consolidation, then lower-dose itraconazole for longer-term maintenance to help prevent relapse. The exact plan may differ for people without HIV, people who are pregnant, or those with central nervous system involvement.
Why is Amphotericin B given first for talaromycosis?
Intravenous Amphotericin B clears the fungus from the bloodstream faster than starting with oral itraconazole and is commonly used for the initial phase. The liposomal form is generally less stressful to the kidneys than the deoxycholate form, but it can still cause infusion reactions, kidney problems, electrolyte loss, and anemia.
How do I take itraconazole during treatment for talaromycosis?
Itraconazole capsules are usually taken with a full meal and depend on stomach acid for absorption, while the oral solution is generally taken on an empty stomach. The products are not interchangeable, and antacids or proton-pump inhibitors can affect absorption, so ask your doctor or pharmacist before changing them.
When should a person with HIV begin ART during talaromycosis treatment?
The care team often plans to start or restart antiretroviral therapy about one to two weeks after antifungal treatment begins. New or worsening fever or cough after ART may be immune reconstitution inflammatory syndrome, but it can also signal drug resistance, poor absorption, or another infection and needs prompt assessment.
What side effects should I report during IV Amphotericin B treatment?
Report fever, chills, or shaking during the infusion, changes in urine output or dark urine, muscle cramps, weakness, a racing heartbeat, unusual tiredness, or shortness of breath. Clinicians commonly monitor kidney function, potassium, magnesium, and blood counts because Amphotericin B can affect the kidneys, lower electrolytes, and cause anemia.
How long does maintenance therapy last for talaromycosis?
For people with HIV, maintenance itraconazole commonly continues until at least 12 months of treatment have been completed and the CD4 count has remained above 100 cells/µL for at least six months with effective viral suppression. People without HIV should not stop maintenance therapy without advice from their specialist.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Talaromycosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I receiving the liposomal or the deoxycholate formulation of Amphotericin B, and how does this affect my risk for kidney issues?
  2. 2.Why is Amphotericin B preferred for my induction phase instead of an oral medication like Itraconazole?
  3. 3.How often will my potassium, magnesium, and kidney function be checked while I'm on IV treatment?
  4. 4.If I have HIV, exactly when do you plan to start or restart my antiretroviral therapy (ART)?
  5. 5.What are the signs of IRIS I should be looking for once I start my HIV medications?
  6. 6.How will we monitor the levels of Itraconazole in my blood during the consolidation phase to ensure the dose is right for me?

References

References (11)
  1. 1

    A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis.

    Le T, Kinh NV, Cuc NTK, et al.

    The New England journal of medicine 2017; (376(24)):2329-2340 doi:10.1056/NEJMoa1613306.

    PMID: 28614691
  2. 2

    Gastrointestinal Talaromyces marneffei infection in a man with AIDS: A case report.

    Peng R, Peng Z, Mou M, et al.

    Medicine 2023; (102(14)):e33424 doi:10.1097/MD.0000000000033424.

    PMID: 37026934
  3. 3

    Single high-dose liposomal amphotericin B plus B/F/TAF for AIDS-associated talaromycosis in China: a multicentre randomised controlled trial protocol.

    Yan X, Meng X, Song W, et al.

    BMJ open 2025; (15(11)):e105648 doi:10.1136/bmjopen-2025-105648.

    PMID: 41263912
  4. 4

    Efficacy of different antifungal drugs as initial treatment for patients with talaromycosis: A systematic review and meta-analysis.

    Sheng L, Shen Q, Zhou J

    Journal de mycologie medicale 2021; (31(1)):101108 doi:10.1016/j.mycmed.2020.101108.

    PMID: 33370708
  5. 5

    Amphotericin B Colloidal Dispersion is Efficacious and Safe for the Management of Talaromycosis in HIV-Infected Patients: Results of a Retrospective Cohort Study in China.

    Liu M, Yang H, Liu Q, et al.

    Infection and drug resistance 2024; (17()):5581-5593 doi:10.2147/IDR.S481856.

    PMID: 39697558
  6. 6

    Severe anemia, severe leukopenia, and severe thrombocytopenia of amphotericin B deoxycholate-based induction therapy in patients with HIV-associated talaromycosis: a subgroup analysis of a prospective multicenter cohort study.

    Zhou Y, Lu T, Li Y, et al.

    BMC infectious diseases 2023; (23(1)):707 doi:10.1186/s12879-023-08394-7.

    PMID: 37864131
  7. 7

    Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei.

    Stott KE, Le T, Nguyen T, et al.

    Antimicrobial agents and chemotherapy 2021; (65(11)):e0063621 doi:10.1128/AAC.00636-21.

    PMID: 34370587
  8. 8

    Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment.

    Kaewpoowat Q, Chaiwarith R, Yasri S, et al.

    The Journal of antimicrobial chemotherapy 2021; (76(4)):1041-1045 doi:10.1093/jac/dkaa521.

    PMID: 33349869
  9. 9

    HIV-associated talaromycosis: Does timing of antiretroviral therapy matter?

    Qin Y, Zhou Y, Liu S, et al.

    The Journal of infection 2022; (84(3)):410-417 doi:10.1016/j.jinf.2021.12.032.

    PMID: 34963636
  10. 10

    Clinical characteristics and prognosis of Talaromycosis marneffei associated immune reconstitution inflammatory syndrome in AIDS patients.

    Zhang Q, Zhang H, Guo P, et al.

    PLoS neglected tropical diseases 2024; (18(10)):e0012609 doi:10.1371/journal.pntd.0012609.

    PMID: 39423234
  11. 11

    Talaromycosis-associated immune reconstitution inflammatory syndrome exhibits immune dysregulation in patients with acquired immunodeficiency syndrome.

    Zhao B, Zhang Q, Guo P, et al.

    PLoS neglected tropical diseases 2026; (20(9)):e0014695 doi:10.1371/journal.pntd.0014695.

    PMID: 42679001

This page is for informational purposes only and does not constitute medical advice. An infectious disease specialist should tailor talaromycosis treatment, monitoring, and ART timing to your situation.